The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1558
ISSUE 1558
October 22, 2018
OTC Brimonidine (Lumify) for Ocular Redness
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
October 22, 2018 (Issue: 1558)
The FDA has approved an over-the-counter (OTC)
0.025% ophthalmic formulation of the selective
alpha2-adrenergic agonist brimonidine tartrate (Lumify
– Bausch & Lomb) for treatment of ocular redness in
adults and children ≥5 years old. Lumify is the first
brimonidine product to be approved for OTC use.
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: OTC Brimonidine (Lumify) for Ocular Redness
Article code: 1558c
Electronic, downloadable article - $45
Article code: 1558c
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
